Stephens initiated coverage of DermTech with a rating of Overweight and set a new price target of $26.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/18/2022 | $48.00 | Outperform | Oppenheimer |
| 6/14/2022 | $38.00 → $19.00 | Buy | BTIG Research |
| 1/7/2022 | $26.00 | Overweight | Stephens |
| 1/7/2022 | Overweight | Stephens & Co. | |
| 10/15/2021 | $50.00 | Outperform | Cowen |
Oppenheimer resumed coverage of DermTech with a rating of Outperform and set a new price target of $48.00
BTIG Research reiterated coverage of DermTech with a rating of Buy and set a new price target of $19.00 from $38.00 previously
Stephens initiated coverage of DermTech with a rating of Overweight and set a new price target of $26.00
8-K - DermTech, Inc. (0001651944) (Filer)
8-K - DermTech, Inc. (0001651944) (Filer)
8-K - DermTech, Inc. (0001651944) (Filer)
4 - DermTech, Inc. (0001651944) (Issuer)
4 - DermTech, Inc. (0001651944) (Issuer)
4 - DermTech, Inc. (0001651944) (Issuer)
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the Company's strategic alternatives review process. Currently, the Company intends to continue its laboratory operations and processing orders for the DermTech Melanoma Test (DMT), while simultaneously conducting a process to sell substantially all of its assets. Through the bankruptcy process, the Company intends to safeguard the interest of stakeholders and maximize the value of its assets. DermTech
- Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year - Test revenue increased 7 percent versus the first quarter of 2023 DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its first-quarter 2024 financial results. First-Quarter 2024 Financial Results Billable sample volume declined 14 percent from the first quarter of 2023 to approximately 15,360. Test revenue was $3.7 million, up 7 percent from the first quarter of 2023, primarily due to a higher ASP for the DMT. Total revenue was $3.8 million, an 11 percent increase from
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction involving the Company. There can be no assurance, however, that the strategic review process will result in any such transaction or if a transaction is undertaken, that such transaction would close in
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction involving the Company. There can be no assurance, however, that the strategic review process will result in any such transaction or if a transaction is undertaken, that such transaction would close in
- Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 55 percent year-over-year - Test revenue increased 38 percent versus the fourth quarter of 2022 - Estimated cash runway into the first quarter of 2025 DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 financial results. "We reported sustained improvement in many of our key performance indicators during the second half of last year and will continue emphasizing average selling price (ASP) and revenue growth in 2024," said Bret Christensen, CEO, DermTech. "We've aligned our commer
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2023 operating and financial results. In advance of the call on February 29, 2024, DermTech will issue its fourth-quarter 2023 earnings press release. For participants interested in asking questions during the teleconference, please register using the following link. After registering for the event, a confirmation e-mail will be sent with a meeting invitation and access information. Registration is open during
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DermTech, Inc. ("DermTech" or the "Company") (NASDAQ:DMTK) investors that a lawsuit filed on behalf of investors that purchased DermTech securities between May 3, 2022 through November 3, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DermTech, Inc. ("DermTech" or the "Company") (NASDAQ:DMTK) investors that a lawsuit filed on behalf of investors that purchased DermTech securities between May 3, 2022 through November 3, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech's overall commercial strategy and execution. Commenting on Mr. Aguillard's appointment, Bret Christensen, DermTech's CEO said, "I'd like to welcome Mark to the team. We are confident that his demonstrated success and wide breadth of commercial and payer access experience will serve us well during this transformational period as we focus on generating reimbursed tests to grow revenue. Mark's leadership will be i
SC 13G - DermTech, Inc. (0001651944) (Subject)
SC 13G/A - DermTech, Inc. (0001651944) (Subject)
SC 13D/A - DermTech, Inc. (0001651944) (Subject)